Studying T Cells in Blood and Bone Marrow Samples From Patients With Multiple Myeloma
Strategies to Isolate and Expand Myeloma Specific T-cells Using Autologous B Cells as Antigen Presenting Cell B-APC
RATIONALE: Studying samples of blood and bone marrow from patients with cancer in the laboratory may help doctors learn more about T cells and plan better treatment for multiple myeloma.
PURPOSE: This research study is looking at T cells in blood and bone marrow samples from patients with multiple myeloma.
研究概览
地位
条件
详细说明
OBJECTIVES:
Primary
- To evaluate the feasibility of expanding myeloma-specific T cells using autologous ex vivo expanded B cells loaded with myeloma antigens as antigen-presenting cells (B-APCs) in peripheral blood and bone marrow samples from patients with multiple myeloma.
Secondary
- To examine the feasibility of selecting and expanding myeloma-specific T cells ex vivo using interferon γ release and CD3/CD28 stimulation.
OUTLINE: Peripheral blood and bone marrow samples are collected periodically for laboratory studies. Samples are analyzed to assess the feasibility of expanding autologous B cells ex vivo using CD40L and IL-4; the antigen-presenting phenotype of autologous B-cell antigen-presenting cells (B-APCs) using flow cytometry; and the antigen-presenting function of B-APCs using ELISPOT and chromium-release assay. Myeloma-specific interferon γ secreting T cells are isolated and selected using Miltenyi beads. The selected myeloma-specific T cells are expanded ex vivo using anti CD3/CD28 beads.
研究类型
注册 (实际的)
联系人和位置
学习地点
-
-
Michigan
-
Detroit、Michigan、美国、48201-1379
- Barbara Ann Karmanos Cancer Institute
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
描述
DISEASE CHARACTERISTICS:
- Diagnosis of multiple myeloma
PATIENT CHARACTERISTICS:
- Not specified
PRIOR CONCURRENT THERAPY:
- Not specified
学习计划
研究是如何设计的？
设计细节
研究衡量的是什么？
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
Percentage of Myeloma-specific T Cells ex Vivo Expanded Using Flow Cytometry
大体时间：Collection of PBMCs over a period of 9-12 months, and the laboratory component will be performed over another year.
|
Collection of PBMCs over a period of 9-12 months, and the laboratory component will be performed over another year.
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
Cell Counts of Myeloma-specific T Cells ex Vivo Expanded Before and After CD3/CD28 Stimulation
大体时间：Collection of PBMCs over a period of 9-12 months, and the laboratory component will be performed over another year.
|
Collection of PBMCs over a period of 9-12 months, and the laboratory component will be performed over another year.
|
合作者和调查者
调查人员
- 首席研究员：Zaid Al-Kadhimi, MD、Barbara Ann Karmanos Cancer Institute
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (估计)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.
flow cytometry的临床试验
-
Assistance Publique - Hôpitaux de Paris招聘中
-
Fondazione IRCCS Ca' Granda, Ospedale Maggiore...Dr Anna Lavizzari; Dr Francesca Gaia Ciuffini完全的
-
Myanmar Oxford Clinical Research UnitLao-Oxford-Mahosot Hospital Wellcome Trust Research Unit; Medical Action Myanmar; Department of...完全的
-
Centre Chirurgical Marie Lannelongue未知